Literature DB >> 16534757

Unilateral pallidotomy for hemidystonia.

Ahmed Alkhani1, Saeed Bohlega.   

Abstract

Hemidystonia is a clinical presentation of many pathological conditions that can affect the basal ganglia. It is usually a refractory condition to current medical treatment. Recently, stereotactic procedures such as radiofrequency lesioning or deep brain stimulation provided hope for patients with dystonia; we are reporting the clinical outcome of a patient with hemidystonia treated with unilateral pallidotomy. A 15-year-old boy with no family history of movement disorders and normal perinatal history is presented. He started to have progressive dystonic contractions in the right hand and extended to involve both the upper and lower extremities in the right side over a period of 3 years. He was subjected to a left-sided posteroventral pallidotomy. Postoperatively, his hemidystonia improved over a period of a few weeks. The Unified Dystonia Rating Scale improved by 84%. He maintained the improvements for the 2-year postoperative follow-up period. No complications were encountered. Clinical presentation, surgical techniques, and surgical results are presented. In conclusion, hemidystonia may significantly respond to a contralateral posteroventral pallidotomy.

Entities:  

Mesh:

Year:  2006        PMID: 16534757     DOI: 10.1002/mds.20838

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  3 in total

Review 1.  What happened to posteroventral pallidotomy for Parkinson's disease and dystonia?

Authors:  Robert E Gross
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

2.  A rat model of hemidystonia induced by 3-nitropropionic acid.

Authors:  Huan-Guang Liu; Yu Ma; Da-Wei Meng; An-Chao Yang; Jian-Guo Zhang
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

3.  Safety and efficacy of unilateral and bilateral pallidotomy for primary dystonia.

Authors:  Shiro Horisawa; Atsushi Fukui; Nobuhiko Takeda; Takakazu Kawamata; Takaomi Taira
Journal:  Ann Clin Transl Neurol       Date:  2021-03-15       Impact factor: 4.511

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.